Élena Elez

19.7k total citations · 6 hit papers
212 papers, 6.1k citations indexed

About

Élena Elez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Élena Elez has authored 212 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Oncology, 74 papers in Pulmonary and Respiratory Medicine and 51 papers in Cancer Research. Recurrent topics in Élena Elez's work include Colorectal Cancer Treatments and Studies (145 papers), Cancer Genomics and Diagnostics (47 papers) and Genetic factors in colorectal cancer (42 papers). Élena Elez is often cited by papers focused on Colorectal Cancer Treatments and Studies (145 papers), Cancer Genomics and Diagnostics (47 papers) and Genetic factors in colorectal cancer (42 papers). Élena Elez collaborates with scholars based in Spain, United States and Italy. Élena Elez's co-authors include Josep Tabernero, Sanatan Saraf, Guillem Argilés, Patrick A. Ott, Javier Ros, Takayuki Yoshino, Eric Van Cutsem, Davide Ciardiello, Janice M. Mehnert and Teresa Macarulla and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Élena Elez

201 papers receiving 6.0k citations

Hit Papers

Safety and Antitumor Activity of Pembrolizumab in Advance... 2017 2026 2020 2023 2017 2017 2021 2020 2023 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    2017 377 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
  2. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
    2017 363 citations Patrick A. Ott, Élena Elez et al. Journal of Clinical Oncology profile →
  3. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
    2021 331 citations Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology profile →
  4. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
    2020 314 citations Élena Elez et al. profile →
  5. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    2023 183 citations Eric Van Cutsem, Élena Elez et al. profile →
  6. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    2023 96 citations Takayuki Yoshino, Fotios Loupakis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Élena Elez Spain 38 4.5k 1.7k 1.6k 1.4k 1.2k 212 6.1k
Michael J. Pishvaian United States 40 3.8k 0.8× 1.9k 1.1× 614 0.4× 1.1k 0.8× 1.5k 1.2× 216 5.8k
Zsofia K. Stadler United States 39 3.8k 0.8× 1.7k 1.0× 2.1k 1.3× 1.2k 0.9× 2.4k 1.9× 191 6.5k
Allen Lee Cohn United States 38 4.7k 1.0× 1.5k 0.9× 1.0k 0.6× 2.4k 1.7× 1.3k 1.0× 159 6.9k
Christophe Rosty Australia 42 4.4k 1.0× 2.7k 1.6× 2.3k 1.5× 1.4k 1.0× 1.6k 1.3× 134 7.2k
Kyung-Hun Lee South Korea 35 4.1k 0.9× 1.6k 1.0× 602 0.4× 2.0k 1.5× 1.5k 1.2× 216 6.0k
Nilofer S. Azad United States 41 3.8k 0.8× 2.3k 1.4× 909 0.6× 1.4k 1.0× 1.3k 1.0× 205 6.3k
Ryan B. Corcoran United States 36 3.7k 0.8× 4.9k 2.9× 1.6k 1.0× 1.7k 1.2× 2.1k 1.7× 132 8.1k
Miao‐Zhen Qiu China 38 2.5k 0.6× 1.6k 1.0× 595 0.4× 1.6k 1.2× 1.3k 1.0× 165 4.9k
Jean‐Pierre Delord France 43 5.5k 1.2× 2.2k 1.3× 610 0.4× 2.0k 1.5× 1.1k 0.9× 260 8.4k
Lori J. Wirth United States 48 4.3k 0.9× 2.0k 1.2× 975 0.6× 2.4k 1.7× 961 0.8× 260 9.9k

Countries citing papers authored by Élena Elez

Since Specialization
Citations

This map shows the geographic impact of Élena Elez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Élena Elez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Élena Elez more than expected).

Fields of papers citing papers by Élena Elez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Élena Elez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Élena Elez. The network helps show where Élena Elez may publish in the future.

Co-authorship network of co-authors of Élena Elez

This figure shows the co-authorship network connecting the top 25 collaborators of Élena Elez. A scholar is included among the top collaborators of Élena Elez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Élena Elez. Élena Elez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tosi, Federica, Gianluca Mauri, Erica Bonazzina, et al.. (2025). Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies. Drugs. 86(1). 37–57. 1 indexed citations
2.
González‐Flores, Encarnación, et al.. (2025). Gender and sex differences in colorectal cancer screening, diagnosis and treatment. Clinical & Translational Oncology. 27(7). 2825–2837. 8 indexed citations
3.
Baraibar, Iosune, N. Saoudi Gonzalez, Javier Ros, et al.. (2024). Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer. International Journal of Molecular Sciences. 25(13). 6967–6967. 6 indexed citations
4.
Strickler, John H., Andrea Cercek, Salvatore Siena, et al.. (2024). Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).. Journal of Clinical Oncology. 42(16_suppl). 3509–3509. 2 indexed citations
5.
6.
Ros, Javier, Iosune Baraibar, N. Saoudi Gonzalez, et al.. (2024). Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. International Journal of Molecular Sciences. 25(6). 3304–3304. 21 indexed citations
7.
Montés, Ana Fernández, Élena Elez, Juan de la Haba-Rodríguez, et al.. (2023). Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology. Clinical & Translational Oncology. 26(1). 98–108. 1 indexed citations
8.
Elez, Élena, Dale R. Shepard, Cristina Smolenschi, Tanios Bekaii‐Saab, & J. Jac. (2023). P-58 An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma. Annals of Oncology. 34. S34–S35. 1 indexed citations
9.
Tabernero, Josep, Axel Grothey, Eric Van Cutsem, et al.. (2021). Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology. 39(4). 273–284. 331 indexed citations breakdown →
10.
Kagawa, Yoshinori, Élena Elez, Jesús García‐Foncillas, et al.. (2021). Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clinical Cancer Research. 27(9). 2515–2522. 45 indexed citations
11.
Serna, Garazi, Franco Cecchi, Roberta Fasani, et al.. (2019). Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports. 9(1). 13568–13568. 11 indexed citations
12.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2018). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Obstetrical & Gynecological Survey. 73(1). 26–27. 25 indexed citations
13.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(22). 2535–2541. 377 indexed citations breakdown →
14.
Sveen, Anita, Jarle Bruun, Peter W. Eide, et al.. (2017). Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research. 24(4). 794–806. 173 indexed citations
15.
Azuara, Daniel, Cristina Santos, Adriana López‐Doriga, et al.. (2016). Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Molecular Cancer Therapeutics. 15(5). 1106–1112. 12 indexed citations
16.
Martínez‐Cardús, Anna, Sebastián Morán, Eva Musulén, et al.. (2016). Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology. 151(5). 961–972. 37 indexed citations
17.
Cutsem, Eric Van, Cathy Eng, Elżbieta Nowara, et al.. (2014). Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer. Clinical Cancer Research. 20(16). 4240–4250. 92 indexed citations
18.
Κάτσιλα, Θεοδώρα, Josep Gregori, Teresa Macarulla, et al.. (2014). Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. Clinical Cancer Research. 20(24). 6346–6356. 22 indexed citations
19.
Cervantes, Andrés, Élena Elez, Desamparados Roda, et al.. (2012). Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4764–4774. 119 indexed citations
20.
Dopeso, Higinio, Silvia Mateo‐Lozano, Élena Elez, et al.. (2010). Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment. Clinical Cancer Research. 16(8). 2375–2382. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Pishvaian Breakdown of academic impact, for papers by Zsofia K. Stadler Breakdown of academic impact, for papers by Allen Lee Cohn Breakdown of academic impact, for papers by Christophe Rosty Breakdown of academic impact, for papers by Kyung-Hun Lee Breakdown of academic impact, for papers by Nilofer S. Azad Breakdown of academic impact, for papers by Ryan B. Corcoran Breakdown of academic impact, for papers by Miao‐Zhen Qiu Breakdown of academic impact, for papers by Jean‐Pierre Delord Breakdown of academic impact, for papers by Lori J. Wirth
Rankless by CCL
2026